Biohaven Ltd. (BHVN)
Biohaven is a New Haven, Connecticut biopharmaceutical company developing treatments for immune, nerve and metabolic diseases. It last closed at $13.24 on Nov 17, down 4.20% on the day. The average 12-month price target from 3 analysts is $20.33 (+53.6% from the last close), with a high of $32.00 and a low of $10.00. Analyst consensus is Hold, based on the latest ratings from 3 firms (1 buy, 2 hold, 0 sell). In the past 30 days there were 2 dark pool prints totaling $1.1M, the largest $654K.
Key Stats
Last 12 monthsNot reported for this period.
From BHVN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 29). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 3 analysts who set a price target on BHVN in the past 90 days. The average target is $20.33, with a high of $32.00 and a low of $10.00, compared with the last close of $13.24.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 31 | Canaccord Genuity | Maintained | Buy | $32 |
| Sep 10 | HC Wainwright & Co. | Reiterated | Hold | $10 |
| Sep 8 | RBC Capital | Downgrade | Hold | $19 |
| Aug 12 | Morgan Stanley | Maintained | Buy | $19 |
| Jun 29 | B of A Securities | Downgrade | Sell | $11 |
Technical Analysis
The stock is 10% below its 20 day and 2% below its 50 day average. It is 7% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 44). The nearest support is the swing low (Jul 30) at $13.13, and the nearest resistance the Pivot at $13.44.
| RSI (14) | 44.26 | Middle of its range | Neutral |
| MACD | 0.16 | Below its signal line | Bearish |
| Stochastic | 10.2 | Near the bottom of its range | Oversold |
| ADX (14) | 22.5 | Weak trend | |
| Williams %R | -98.2 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -109.9 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −15.3% | Change over 10 sessions | Bearish |
| ATR (14) | $0.98 | Typical daily range, 7.4% of price |
| RSI (14) | 49.64 | Middle of its range | Neutral |
| MACD | 0.26 | Below its signal line | Bearish |
| Stochastic | 41.7 | Middle of its range | Neutral |
| ADX (14) | 20.0 | No clear trend | |
| Williams %R | -66.3 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -41.6 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +4.2% | Change over 10 sessions | Bullish |
| ATR (14) | $2.26 | Typical daily range, 17.0% of price |
What happened before
See how BHVN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How BHVN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2022.
Whale Options Flow
90DNo whale options trades in BHVN in the last 90 days.
Dark Pool
30DBHVN Institutional Ownership
Full report →- ●133 buying vs 133 selling
- ●Held by funds -0.1 pts
- ▲Funds holding +8
- ▼Superinvestors: 2 added, 3 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 303 | 295 | +2.7% |
| In funds' top 10 | 8 | 9 | −11.1% |
| Held by funds | 93.5% | 93.6% | −0.1 pts |
| New / increased | 48 / 85 | 49 / 108 | −15.3% |
| Reduced / sold out | 95 / 38 | 87 / 33 | +10.8% |
| Put/call ratio | 0.16 | 0.00 | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BHVN is in one of them and how their past BHVN trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered BHVN in an article yet. Here's the latest on the wider market.
About Biohaven
Biohaven is a biopharmaceutical company based in New Haven, Connecticut. It develops treatments in immunology, neuroscience and oncology. Its main programs include a group of drugs that remove disease-causing proteins from the body for immune conditions such as Graves' disease and IgA nephropathy, a candidate for epilepsy, and a program for muscle and metabolic conditions, including obesity. Its treatments are aimed at patients with these diseases.
- Headquarters
- New Haven, CT




